0.02 KE), at every two weeks, repeated 4 times 3rdduration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil
Sponsors
Department of Gastroenterological Surgery I, Hokkaido University Graduated School of Medicine, Department of Breast and Endocrine Surgery, Hokkaido University Hospital
Conditions
A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent breast cancersSurvivin-expressing advanced/recurrent colorectal cancer patients or patients who refuse standard cancer therapy
Phase 2
A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent breast cancers
Active, not recruitingJPRN-UMIN000007507
Start: 2012-03-01Target: 40Updated: 2026-06-29
A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent colorectal cancers
Active, not recruitingJPRN-UMIN000007506
Start: 2012-03-01Target: 35Updated: 2026-06-29